Idexx Laboratories patented a method for diagnosing kidney disease in canines by detecting decreased inosine levels in patient samples. Treatment options include dialysis, low-phosphorous, and low-protein diet. The invention utilizes specific biomarkers for accurate diagnosis and treatment of renal disease in dogs. GlobalData’s report on Idexx Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Idexx Laboratories Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Idexx Laboratories, was a key innovation area identified from patents. Idexx Laboratories's grant share as of April 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

Diagnosis and treatment of kidney disease in canines

Source: United States Patent and Trademark Office (USPTO). Credit: Idexx Laboratories Inc

A recently granted patent (Publication Number: US11933792B2) discloses a method for diagnosing and treating kidney disease in canines. The method involves detecting the amount of inosine in a sample from a canine suspected of suffering from kidney disease. A decreased amount of inosine compared to a control indicates kidney disease, leading to treatment options such as dialysis, a low-phosphorous and protein diet, or a combination of both.

The detection of inosine levels is carried out using specific antibodies or antigen binding fragments in immunoassays like ELISA, western blot, or radio immunoassay. These antibodies can be detectably labeled, immobilized on a solid support, and can include monoclonal antibodies, single-chain antibodies, or polyclonal antibodies. The method also allows for the determination of inosine levels using liquid chromatography/mass spectrometry or mass spectrometry. The diagnosis covers various types of kidney diseases, including glomerular and tubular kidney diseases, with the aim of identifying the condition before it progresses to stage 3. Samples for analysis can include urine, blood, serum, or plasma from the canine patient.

To know more about GlobalData’s detailed insights on Idexx Laboratories, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.